Coronavirus tally: FDA panel oks Moderna vaccine for children ages 6 to 17, to review Moderna and Pfizer shots for small children

A panel of advisers to the Food and Drug Administration endorsed a second brand of COVID-19 vaccine for school-age children and teens, the Associated Press reported. The group voted unanimously that Moderna’s vaccine is safe and effective enough to give kids ages 6 to 17. If the FDA agrees, it would become the second option for those children, joining Pfizer’s vaccine. The same panel will meet Wednesday to review both Moderna and Pfizer vaccines for children below the age of five, the last group to be added to the vaccine program.
U.S. cases are averaging 105,605 a day, up 7% from two weeks ago, according to a New York Times tracker. The country is averaging 29,728 hospitalizations a day, up 8% from two weeks ago. The daily death toll has fallen to 322 on average, up 8% from two weeks ago. On a global basis, total cases are now above 536.6 million. Total deaths are above 6.31 million, according to data aggregated by Johns Hopkins University, with the U.S. still leading the way with 85.8 million cases and 1,011,925 deaths.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.